Certuity LLC Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Certuity LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,580 shares of the pharmaceutical company’s stock after purchasing an additional 433 shares during the quarter. Certuity LLC’s holdings in Vertex Pharmaceuticals were worth $1,050,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in VRTX. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals in the third quarter valued at approximately $25,000. Arlington Trust Co LLC grew its position in shares of Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 33 shares during the last quarter. Fortitude Family Office LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $30,000. Baystate Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares during the last quarter. Finally, NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals in the third quarter valued at $34,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price on the stock in a research report on Thursday, April 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Wells Fargo & Company boosted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Truist Financial raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Guggenheim increased their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $429.45.

Insider Activity

In related news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Ourania Tatsis sold 354 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. In the last three months, insiders sold 12,381 shares of company stock valued at $5,203,249. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.5 %

NASDAQ VRTX traded down $2.16 during trading hours on Tuesday, reaching $394.04. 588,485 shares of the company traded hands, compared to its average volume of 1,212,384. The stock has a market capitalization of $101.84 billion, a PE ratio of 28.52, a PEG ratio of 1.87 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 12 month low of $320.01 and a 12 month high of $448.40. The company has a 50 day moving average of $411.08 and a two-hundred day moving average of $399.37. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter last year, the business posted $3.33 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.